Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

LaNova Medicines Announces IND Approval of LM-168 by NMPA

  • 2025-06-11

  • Share:

SHANGHAI, June 11th, 2025 – LaNova Medicines Ltd. announced that the investigational new drug (IND) of LM-168, a next-generation anti-CTLA-4 antibody, has been approved by China NMPA.